vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与HAVERTY FURNITURE COMPANIES INC（HVT）财务数据对比。点击上方公司名可切换其他公司
HAVERTY FURNITURE COMPANIES INC的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.3倍（$201.9M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 4.2%，领先30.3%），HAVERTY FURNITURE COMPANIES INC同比增速更快（9.5% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $3.0M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 4.8%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
该企业原名为国际鞋业公司，1911年由两家鞋企合并成立于美国密苏里州克莱顿，后开展多元化业务并逐步退出制鞋领域，最终更名为家具品牌国际，是美国家居行业知名企业，曾拥有布罗伊希尔等多个知名家具品牌。
CPRX vs HVT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $201.9M |
| 净利润 | $52.7M | $8.5M |
| 毛利率 | 82.9% | 60.4% |
| 营业利润率 | 40.5% | 5.3% |
| 净利率 | 34.5% | 4.2% |
| 营收同比 | 7.6% | 9.5% |
| 净利润同比 | -5.8% | 4.1% |
| 每股收益（稀释后） | $0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $201.9M | ||
| Q3 25 | $148.4M | $194.5M | ||
| Q2 25 | $146.6M | $181.0M | ||
| Q1 25 | $141.4M | $181.6M | ||
| Q4 24 | $141.8M | $184.4M | ||
| Q3 24 | $128.7M | $175.9M | ||
| Q2 24 | $122.7M | $178.6M | ||
| Q1 24 | $98.5M | $184.0M |
| Q4 25 | $52.7M | $8.5M | ||
| Q3 25 | $52.8M | $4.7M | ||
| Q2 25 | $52.1M | $2.7M | ||
| Q1 25 | $56.7M | $3.8M | ||
| Q4 24 | $55.9M | $8.2M | ||
| Q3 24 | $43.9M | $4.9M | ||
| Q2 24 | $40.8M | $4.4M | ||
| Q1 24 | $23.3M | $2.4M |
| Q4 25 | 82.9% | 60.4% | ||
| Q3 25 | 84.7% | 60.3% | ||
| Q2 25 | 85.9% | 60.8% | ||
| Q1 25 | 87.3% | 61.2% | ||
| Q4 24 | 84.7% | 61.9% | ||
| Q3 24 | 85.0% | 60.2% | ||
| Q2 24 | 87.4% | 60.4% | ||
| Q1 24 | 87.3% | 60.3% |
| Q4 25 | 40.5% | 5.3% | ||
| Q3 25 | 44.7% | 3.3% | ||
| Q2 25 | 45.2% | 2.4% | ||
| Q1 25 | 44.8% | 2.9% | ||
| Q4 24 | 44.3% | 5.2% | ||
| Q3 24 | 39.6% | 3.9% | ||
| Q2 24 | 44.2% | 3.6% | ||
| Q1 24 | 27.5% | 1.7% |
| Q4 25 | 34.5% | 4.2% | ||
| Q3 25 | 35.6% | 2.4% | ||
| Q2 25 | 35.6% | 1.5% | ||
| Q1 25 | 40.1% | 2.1% | ||
| Q4 24 | 39.4% | 4.4% | ||
| Q3 24 | 34.1% | 2.8% | ||
| Q2 24 | 33.2% | 2.5% | ||
| Q1 24 | 23.6% | 1.3% |
| Q4 25 | $0.40 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.41 | — | ||
| Q1 25 | $0.45 | — | ||
| Q4 24 | $0.44 | — | ||
| Q3 24 | $0.35 | — | ||
| Q2 24 | $0.33 | — | ||
| Q1 24 | $0.19 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $125.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $307.9M |
| 总资产 | $1.1B | $649.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $125.3M | ||
| Q3 25 | $689.9M | $130.5M | ||
| Q2 25 | $652.8M | $107.4M | ||
| Q1 25 | $580.7M | $111.9M | ||
| Q4 24 | $517.6M | $120.0M | ||
| Q3 24 | $442.3M | $121.2M | ||
| Q2 24 | $375.7M | $109.9M | ||
| Q1 24 | $310.4M | $111.8M |
| Q4 25 | $954.3M | $307.9M | ||
| Q3 25 | $920.2M | $306.0M | ||
| Q2 25 | $856.0M | $304.9M | ||
| Q1 25 | $794.3M | $305.4M | ||
| Q4 24 | $727.6M | $307.6M | ||
| Q3 24 | $660.9M | $307.8M | ||
| Q2 24 | $608.7M | $307.1M | ||
| Q1 24 | $561.4M | $306.7M |
| Q4 25 | $1.1B | $649.1M | ||
| Q3 25 | $1.1B | $651.7M | ||
| Q2 25 | $971.9M | $642.7M | ||
| Q1 25 | $908.9M | $642.7M | ||
| Q4 24 | $851.4M | $648.7M | ||
| Q3 24 | $772.0M | $659.3M | ||
| Q2 24 | $706.4M | $642.1M | ||
| Q1 24 | $646.7M | $640.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $7.4M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $3.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 1.5% |
| 资本支出强度资本支出/营收 | 0.0% | 2.2% |
| 现金转化率经营现金流/净利润 | 0.85× | 0.86× |
| 过去12个月自由现金流最近4个季度 | — | $33.0M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $7.4M | ||
| Q3 25 | $32.4M | $31.9M | ||
| Q2 25 | $71.3M | $7.2M | ||
| Q1 25 | $60.0M | $6.2M | ||
| Q4 24 | $70.9M | $16.9M | ||
| Q3 24 | $72.9M | $24.4M | ||
| Q2 24 | $64.1M | $14.4M | ||
| Q1 24 | $31.9M | $3.1M |
| Q4 25 | $44.9M | $3.0M | ||
| Q3 25 | — | $28.3M | ||
| Q2 25 | $71.3M | $1.6M | ||
| Q1 25 | — | $27.0K | ||
| Q4 24 | $70.8M | $9.1M | ||
| Q3 24 | $72.6M | $16.1M | ||
| Q2 24 | $64.1M | $4.9M | ||
| Q1 24 | $31.7M | $-3.3M |
| Q4 25 | 29.4% | 1.5% | ||
| Q3 25 | — | 14.6% | ||
| Q2 25 | 48.6% | 0.9% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 49.9% | 4.9% | ||
| Q3 24 | 56.4% | 9.2% | ||
| Q2 24 | 52.3% | 2.7% | ||
| Q1 24 | 32.2% | -1.8% |
| Q4 25 | 0.0% | 2.2% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 3.1% | ||
| Q1 25 | 0.0% | 3.4% | ||
| Q4 24 | 0.1% | 4.2% | ||
| Q3 24 | 0.2% | 4.7% | ||
| Q2 24 | 0.0% | 5.3% | ||
| Q1 24 | 0.2% | 3.5% |
| Q4 25 | 0.85× | 0.86× | ||
| Q3 25 | 0.61× | 6.75× | ||
| Q2 25 | 1.37× | 2.69× | ||
| Q1 25 | 1.06× | 1.63× | ||
| Q4 24 | 1.27× | 2.06× | ||
| Q3 24 | 1.66× | 4.96× | ||
| Q2 24 | 1.57× | 3.25× | ||
| Q1 24 | 1.37× | 1.31× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
HVT
| Upholstery | $91.0M | 45% |
| Bedroom Furniture | $29.2M | 14% |
| Accessories And Other | $28.4M | 14% |
| Dining Room Furniture | $22.8M | 11% |
| Mattresses | $16.1M | 8% |
| Occasional | $14.4M | 7% |
